HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis

Affiliation auteurs!!!! Error affiliation !!!!
TitreHSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis
Type de publicationJournal Article
Year of Publication2018
AuteursSevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JLuc, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chretien M-L, Bastie JNoel, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A
JournalNATURE COMMUNICATIONS
Volume9
Pagination1431
Date PublishedAPR 12
Type of ArticleArticle
ISSN2041-1723
Résumé

Heat shock protein 27 (HSP27/HSPB1) is a stress-inducible chaperone that facilitates cancer development by its proliferative and anti-apoptotic functions. The OGX-427 antisense oligonucleotide against HSP27 has been reported to be beneficial against idiopathic pulmonary fibrosis. Here we show that OGX-427 is effective in two murine models of thrombopoietin- and JAKV617F-induced myelofibrosis. OGX-427 limits disease progression and is associated with a reduction in spleen weight, in megakaryocyte expansion and, for the JAKV617F model, in fibrosis. HSP27 regulates the proliferation of JAK2V617F-positive cells and interacts directly with JAK2/STAT5. We also show that its expression is increased in both CD34(+) circulating progenitors and in the serum of patients with JAK2-dependent myeloproliferative neoplasms with fibrosis. Our data suggest that HSP27 plays a key role in the pathophysiology of myelofibrosis and represents a new potential therapeutic target for patients with myeloproliferative neoplasms.

DOI10.1038/s41467-018-03627-9